7. Merck & Co.


7. Merck & Co.
2017 cancer sales: $4.11 billion
2024 cancer sales: $13.21 billlion
Rank change: None

Merck’s Keytruda may be stealing the immuno-oncology show these days, but the way Evaluate sees it, the New Jersey drugmaker will still be slated seventh in oncology sales when 2024 comes around.

On the other hand, that year, the pharma giant will register more than $9 billion higher in cancer sales than it did last year, and much of that increase will come thanks to the company’s PD-1 moneymaker.

As anyone who has been following the I-O race knows, lung cancer is the most competitive field for the new generation of cancer fighters, and that’s because it represents a mammoth market—and financial opportunity. Currently, Keytruda leads rivals from Bristol-Myers, AstraZeneca, Roche and the Pfizer-Merck KGaA team in that department, boasting two approvals in the front-line setting to their collective zero.

Keytruda has also impressed in plenty of other cancer types, winning green lights in cancers including head and neck, cervical, lymphoma and more. Its indications across nine collective cancer types will all chip in sales that’ll contribute to its forthcoming leap.

Keytruda won’t be doing all the legwork on its own, though. Merck recently struck a pair of deals to gain access to two promising therapies that it hopes will come up big. Last July, it laid out $8.5 billion for half-ownership of AstraZeneca PARP inhibitor Lynparza, and it followed up this March with a $5.8 billion deal for a 50% stake in Eisai’s Lenvima.

7. Merck & Co.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.